ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study
Recruitment status was Recruiting
This study will examine genome sequencing in clinical research. Genome sequencing is a process in which researchers analyze (or sequence) part or all of the genome from a single person. The human genome is the material in cells that includes thousands of genes. Gene changes that cause or contribute to disease can be passed on from one generation to the next. This study first focuses on heart disease. Later, researchers hope to study other conditions and genes, with the eventual goal of sequencing most or all of participants genes.
Participants ages 45 to 65 years of age and who do not smoke, may be eligible for this study. Patients will come to the NIH Clinical Research Center for an initial study to last about half a day. They will donate a blood sample and complete a short survey. Then they will meet the genetic counselor to learn more about genome sequencing. Those who join the study will undergo the following procedures and evaluations:
- Family history and medical history.
- Measurement of height and blood pressure.
- Noninvasive heart tests, including electrocardiogram and echocardiogram.
- Drawing of about 3 ounces of blood (5 to 6 tablespoons); part of the blood sample will be used for research and another part for clinical testing.
- Multidetector computed tomography (CT), a test to measure coronary artery calcification, that is, condition of inflexibility.
Each patient will receive a letter with results of the clinical laboratory values and evaluations. There will be recommendations for follow-up with the patient s doctors. Risks in this study include exposure to radiation from the CT test. The radiation amount used is about the same that a person normally receives from natural sources, such as from the sun, outer space, and radioactive materials found naturally in the earth s air and soil. Another slight risk involves reactions to a contrast agent that may be used in the echocardiogram. Side effects can be headache, nausea or vomiting, a warm sensation, and dizziness.
With the samples that patients provide, researchers will start by sequencing about 400 genes related to heart disease. Analysis will take months to complete. Genome sequencing is difficult to do, and researchers have much to learn about the genes they sequence and the gene changes they find. If the researchers find gene changes that are important to the health of a participant, they will contact that participant and give him/her the choice of learning such results.
This study may or may not have a direct benefit for participants. Patients would get free clinical testing for cholesterol, diabetes, and other conditions, as well as information about gene changes. Knowledge gained will benefit people in the future as researchers learn about the relationship between gene changes and health.
Coronary Artery Calcification
|Official Title:||ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study|
|Study Start Date:||December 2006|
The purpose of ClinSeq is to pilot large-scale medical sequencing (LSMS) in a clinical research setting. By sequencing targeted regions of a person s genome and returning relevant and individual results to that person, we will begin investigating some of the technical, medical, and genetic counseling issues that accompany the implementation of LSMS in the clinical setting. Specifically, we seek to develop technologic and procedural infrastructures to facilitate this type of research and demonstrate that it is feasible to sequence and interpret large amounts of genomic sequence data and return individual results to subjects.
A cohort of 1,000 individuals selected from the surrounding general population will be evaluated at the NIH Clinical Center for a common set of cardiovascular phenotypic features, including, but not limited to, coronary artery calcification, lipid profiles, and blood pressure. Participants will be selected to fall within a spectrum of coronary artery calcification from normal to disease phenotype based on Framingham scores. During their initial visit, participants will undergo a clinical evaluation, targeted clinical tests, and blood sample collection for genomic analysis. Additionally, they will be asked to provide baseline information about pertinent health behavior and a family history. During their initial visit and as the study progresses, participants may be asked to complete surveys related to their decision to participate in the study and to their decision to learn individual genotype results.
In the beginning of the project functional regions of 400 candidate genes thought to be implicated in the biology of coronary artery disease were sequenced at the NIH Intramural Sequencing Center (NISC). The study is now progressing to a new phase in which most participants will have whole exome sequencing, and selected participants will have whole genome sequencing. ClinSeq will further our understanding of the relative contributions of rare versus common variants to the architecture of common disease. Currently, only direct sequencing can address the question of the frequency of rare variants, which is of particular interest to us. We will test for associations of genomic variants, some of which will be rare, with the cardiovascular phenotype in question, as well as other phenotypes. We have started developing analytic algorithms to distinguish potentially pathogenic genetic alterations from normal variation. Sequence variants deemed clinically relevant will be validated in a CLIA-certified laboratory and the results returned to that subject. ClinSeq is being designed in a way that will provide the long-term potential for pursuing many different clinical projects.
Relatives of ClinSeq participants may be invited to enroll in the study for more limited studies if their participation aids our understanding of the gene variants detected in the probands. For example, these relatives may undergo genetic testing for co-segregation of known or suspected disease-causing variants, and/or phenotyping relevant to the disease in question.
We aim to pilot procedures for generating data, address some of the analytical hurdles of interpreting these data, and develop approaches for the medical and counseling challenges of utilizing the relevant data for clinical research.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00410241
|Contact: Katie L Lewis||(301) email@example.com|
|Contact: Leslie G Biesecker, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|Bethesda, Maryland, United States, 20814|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Leslie G Biesecker, M.D.||National Human Genome Research Institute (NHGRI)|